Signal
Novartis has penned a $2 billion deal for a biotech whose next-gen anti-IgE program could offer a worthy successor to Xolair.
Evidence first: scan the strongest sources, then decide whether to go deeper.
rss
biopharma_dive
Trend in the last 24h
Source links limited
You can inspect the signal and top sources here. Full source links and workflow tools unlock on the flagship sample or in the app.
Evidence preview
- Novartis targets Xolair successor in buyout of startup ExcellergyBioPharma Dive
- Novartis has penned a $2 billion deal for a biotech whose next-gen anti-IgE program could offer a worthy successor to...Fierce Biotech
Overview
Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche’s popular medicine.
Score total
1.01
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%